Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for inflammatory and immune-mediated diseases. Headquartered in San Diego, the company advances drug candidates designed to modulate well-characterized immune signaling pathways.
Ventyx’s reported programs have included selective inhibitors of the NLRP3 inflammasome and TYK2, as well as an S1P1 receptor modulator, with potential applications across gastroenterology, dermatology, rheumatology, and neurology. The company conducts preclinical research and clinical trials to evaluate the safety and efficacy of these compounds as potential oral alternatives to injectable biologic therapies.
